Alkermes Transitions To Novel R&D Products With Learnings From COVID-19
Executive Summary
Built on established products and royalties from drug delivery technology, Alkermes is getting ready to launch its first novel product. Scrip talked to CEO Richard Pops about the preparations.
You may also be interested in...
After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.
Alkermes Expects Gradual Ramp-Up For Lybalvi Launch
Alkermes’ combo pill of olanzapine and samidorphan gets US FDA approval; company predicts $10m first-year sales as schizophrenia/bipolar patients cycle through treatment options, including generics.
Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.